TVTX insider trading
HealthcareTravere Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Company website: www.travere.com
TVTX insider activity at a glance
FilingIQ has scored 524 insider transactions for TVTX since Nov 19, 2020. The most recent filing in our index is dated May 6, 2026.
Across the full history, 0 open-market purchases
and 271 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TVTX insider trades is 61.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TVTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading TVTX
13F funds holding TVTX
Frequently asked
- How many insider trades does FilingIQ track for TVTX?
- FilingIQ tracks 524 Form 4 insider transactions for TVTX (Travere Therapeutics, Inc.), covering filings from Nov 19, 2020 onwards. 111 of those were filed in the last 90 days.
- Are TVTX insiders net buyers or net sellers?
- Across the full Form 4 history for TVTX, 0 transactions (0%) were open-market purchases and 271 (52%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TVTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is TVTX in?
- Travere Therapeutics, Inc. (TVTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.53B.
Methodology & sources
Every TVTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.